Posts Tagged ‘dementia’
Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But new research from the University of Georgia suggests that patients and caregivers may not experience any benefit from the drug in their daily lives. The drug, Leqembi,…
Read MoreLifestyle matters: What we can do in 2024 to optimize cognition and life, delaying cognitive problems even dementia
Walk 10,000 steps a day, cut back alcohol, get better sleep at night, stay socially active — we’re told that changes like these can prevent up to 40 per cent of dementia cases worldwide. Given that dementia is still one of the most feared diseases, why aren’t we pushing our doctors and governments to support…
Read MoreStudy identifies protective brain structure that delays the onset of frontotemporal dementia symptoms over 2 years
Few people had probably heard of frontotemporal dementia until earlier this year, when the family of actor Bruce Willis announced the 68-year-old had been diagnosed with the condition. Frontotemporal dementia is a rare disease – thought to account for only one in every 20 cases of dementia. Symptoms usually develop in a person’s late 50s,…
Read MoreStudy: Playing board games like Chess, Mahjong, Go, helps slow cognitive decline as we age (but with clear differences in neurobiology and improved function)
Playing Board Games May Slow Cognitive Decline, Improve QoL (Medscape): Playing chess or other board games slows cognitive decline and improves quality of life in older patients, results of a new systematic review suggest. … After searching the published literature, Pozzi and his colleagues selected 15 studies for the review. The studies assessed the impact…
Read MoreFour reasons to question “new generation” monoclonal antibody Alzheimer’s drugs such as aducanumab (Aduhelm), lecanemab (Leqembi), donanemab
New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient): A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.
Read MorePrice tag for a questionable Alzheimer’s treatment: $109,000 per patient, per year. Unclear yet: For how many years?
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill (CBS News): The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors…
Read More